Diabetes mellitus does not alter mortality or hospitalisation risk in patients with newly diagnosed heart failure with preserved ejection fraction: Time to rethink pathophysiological models of disease progression

• Published in: Diabetes & vascular disease research Vol. 21; no. 2; p. 14791641231224241
• Main Authors: Gierula, John, Straw, Sam, Cole, Charlotte A, Lowry, Judith E, Paton, Maria F, McGinlay, Melanie, Witte, Klaus K, Grant, Peter J, Wheatcroft, Stephen B, Drozd, Michael, Slater, Thomas A, Cubbon, Richard M, Kearney, Mark T
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.03.2024
• Subjects: Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - diagnosis; Disease Progression; Heart Failure; Hospitalization; Humans; Male; Original; Prognosis; Prospective Studies; Stroke Volume - physiology; Heart failure; mortality; ejection fraction; diabetes; preserved
• ISSN: 1479-1641; 1752-8984
• DOI: 10.1177/14791641231224241

Introduction Type 2 diabetes is a common and adverse prognostic co-morbidity for patients with heart failure with reduced ejection fraction (HFrEF). The effect of diabetes on long-term outcomes for heart failure with preserved ejection fraction (HFpEF) is less established. Methods Prospective cohort study of patients referred to a regional HF clinic with newly diagnosed with HFrEF and HFpEF according to the 2016 European Society of Cardiology guidelines. The association between diabetes, all-cause mortality and hospitalisation was quantified using Kaplan-Meier or Cox regression analysis. Results Between 1st May 2012 and 1st May 2013, of 960 unselected consecutive patients referred with suspected HF, 464 and 314 patients met the criteria for HFpEF and HFrEF respectively. Within HFpEF and HFrEF groups, patients with diabetes were more frequently male and in both groups patients with diabetes were more likely to be treated with β-adrenoceptor antagonists and angiotensin converting enzyme inhibitors. After adjustment for age, sex, medical therapy and co-morbidities, diabetes was associated with increased mortality in individuals with HFrEF (HR 1.46 95% CI: 1.05–2.02; p = .023), but not in those with HFpEF (HR 1.26 95% CI 0.92–1.72; p = .146). Conclusion In unselected patients with newly diagnosed HF, diabetes is not an adverse prognostic marker in patients with HFpEF, but is in HFrEF.